Focus
multiple myeloma
LATEST
FDA Withdraws Approval of Multiple Myeloma Medication, Citing Safety, Efficacy Issues
Pepaxto was deemed to have ‘potential detriment in overall survival’ in patients in a phase 3 trial, prompting the FDA’s decision.
|
Pepaxto was deemed to have ‘potential detriment in overall survival’ in patients in a phase 3 trial, prompting the FDA’s decision.